Nephros, Inc. (OTCMKTS:NEPH) Insider Buys $25,903.20 in Stock

Nephros, Inc. (OTCMKTS:NEPH) insider Daron Evans bought 43,172 shares of Nephros stock in a transaction on Friday, June 14th. The stock was purchased at an average price of $0.60 per share, for a total transaction of $25,903.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NEPH stock traded up $0.04 during trading hours on Friday, hitting $0.62. 180,129 shares of the company were exchanged, compared to its average volume of 14,953. The firm has a market cap of $40.05 million, a P/E ratio of -10.33 and a beta of 0.81. Nephros, Inc. has a 1 year low of $0.41 and a 1 year high of $0.71. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.31 and a quick ratio of 1.65.

Nephros (OTCMKTS:NEPH) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.01). The company had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $1.70 million. Nephros had a negative return on equity of 56.46% and a negative net margin of 52.25%. Analysts expect that Nephros, Inc. will post -0.07 earnings per share for the current fiscal year.

Separately, Taglich Brothers reiterated a “speculative buy” rating on shares of Nephros in a report on Wednesday, April 24th.

COPYRIGHT VIOLATION NOTICE: “Nephros, Inc. (OTCMKTS:NEPH) Insider Buys $25,903.20 in Stock” was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/06/15/nephros-inc-otcmktsneph-insider-buys-25903-20-in-stock.html.

About Nephros

Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Featured Story: Stop Order Uses For Individual Investors

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.